Google subsidiary begins human trials of AI cancer drug

Google subsidiary begins human trials of AI cancer drug

Ondřej Barták
Ondřej Barták
Entrepreneur and Programmer
10. 7. 2025
2 minutes reading · 9 views
Google subsidiary begins human trials of AI cancer drug

Google Subsidiary Launches Human Trials of AI-Developed Cancer Drug

Pharmaceutical company Isomorphic Labs, a subsidiary of Google's parent company Alphabet, is preparing to launch human clinical trials of its cancer drugs. These drugs were developed with the help of AlphaFold 3, an artificial intelligence (AI) system created in collaboration with Google DeepMind. The company, founded in 2021, is now preparing to administer the first doses to patients while also expanding its team, Isomorphic Labs President Colin Murdoch revealed in a recent interview with Fortune magazine.

What Does AlphaFold 3 Actually Do?

AlphaFold 3 is an advanced AI tool designed to predict complex protein structures and molecular interactions, which has helped Isomorphic Labs make significant progress in developing this drug. Cancer drugs are crucial in cancer treatment because they either destroy cancer cells or slow their growth, enabling further therapies. According to the World Health Organization (WHO), approximately 20 million new cancer cases and 9.7 million deaths related to the disease were recorded in 2022. Tools such as AlphaFold 3 have enormous potential for discovering new drugs for terminal illnesses such as cancer.

Funding and Future Plans

In March last year, Isomorphic Labs raised more than $600 million in a funding round led by Thrive Capital. The funds are being used to develop a next-generation AI drug development system and advance programs toward clinical trials. “This funding will accelerate the development of our next-generation drug development system, help advance our programs into clinical development, and is an important step toward our mission of one day solving all diseases with the help of AI,” said Demis Hassabis, CEO of both Isomorphic Labs and Google DeepMind.

Isomorphic Labs has entered into partnerships worth more than $3 billion with pharmaceutical giants such as Novartis and Eli Lilly. The company's goal is to create a cutting-edge drug design system that combines AI with human expertise to develop new drugs with higher success rates and lower costs for both manufacturers and consumers.

AI and Drug Discovery

With the rapid rise of AI, other biotech companies, such as Anima Biotech, Iktos, and Novo Nordisk, are also using the technology to operate more efficiently. Novo Nordisk, for example, signed a $2.76 billion agreement with Valo Health to apply AI to the drug discovery process. According to GlobalData statistics, more than 3,000 drugs have been developed or redesigned using AI technologies, with most still in the early stages and awaiting human clinical trials. Isomorphic Labs' upcoming trials could pave the way for further advances in the application of AI in biotechnology.

Advertisement

Content created with help from UpTier.

SEO and GEO on autopilot. UpTier’s multi-agent systems write and optimize content for search engines and AI answers.

Discover UpTier ↗

Category:AI
Did you enjoy this article?
Discover more interesting posts on our blog
Back to blog

Related posts

Google makes Tasks free for Gemini 4 Hydrogen usersGoogle makes Tasks free for Gemini 4 Hydrogen users
Tasks is becoming available for free to hundreds of millions of Gemini 4 Hydrogen users. Google says it can call businesses, book appointments and complete purchases on their behalf.
1 min read
18. 11. 2026
OpenAI introduces GPT-6.2 Astra and Sol for professional and everyday workOpenAI introduces GPT-6.2 Astra and Sol for professional and everyday work
OpenAI has introduced two models: Astra for complex professional tasks and Sol for everyday work. Both are available in ChatGPT Work, Codex and through the API.
3 min read
17. 11. 2026
Tencent releases Hy4 Flash with image support and a context window of up to 1 million tokensTencent releases Hy4 Flash with image support and a context window of up to 1 million tokens
The lighter Hy4 Flash model targets chat, documents and routine code edits. It accepts text and images, supports tool use and, according to Tencent, matched Claude Haiku 5.5 in tests of everyday tasks.
1 min read
16. 11. 2026
Přihlaste se k odběru našeho newsletteru
Zůstaňte informováni o nejnovějších příspěvcích, exkluzivních nabídkách, a aktualizacích.
CodedTrip

Operated by CodedTrip LLC, USA.

YouTube
TikTok